management of acute lvf
TRANSCRIPT
![Page 1: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/1.jpg)
Management of acute LVF
Presenter : Dr. Gautam ChakmaModerator : Prof. Lallan Prasad
![Page 2: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/2.jpg)
Introduction
• Acute heart failure (AHF)- rapid onset of symptoms and
signs secondary to abnormal cardiac function.
• Acute left ventricular failure (ALVF) is AHF due to
abnormal left ventricular function.
• It is often life threatening and requires urgent treatment.
![Page 3: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/3.jpg)
• AHF-acute de novo/acute decompensation of CHF.• Acuteness-days/weeks/hrs-minutes.• CAD most common aetiology(60–70%), particularly
in elderly.• Younger subjects-DCM, arrhythmia, congenital and
valvular heart disease, myocarditis
![Page 4: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/4.jpg)
Pathophysiology AHF
![Page 5: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/5.jpg)
Causes and precipitating factors in AHF
![Page 6: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/6.jpg)
SIGN AND SYMPTOMS OF ACUTE LVF
![Page 7: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/7.jpg)
AHF with distinct clinical conditions
![Page 8: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/8.jpg)
Classifications of AHFS after AMI utilized in CCU and ICCU
Killip classification• Stage I—No clinical signs of HF.• Stage II—Heart failure. Rales,S3 gallop and pulmonary
venous hypertension.• Stage III—Severe HF. Frank pulmonary oedema with rales
throughout the lung fields• Stage IV—Cardiogenic shock.Hypotension (SBP <90
mmHg), peripheral vasoconstriction (oliguria, cyanosis diaphoresis) .
![Page 9: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/9.jpg)
Diagnosis• Diagnosis of AHF is based on the symptoms and clinical
findings,• Supported by appropriate investigations such as ECG, chest
X-ray, biomarkers, and Doppler echocardiography
![Page 10: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/10.jpg)
• CXR- Cardiomegaly,Kerley’s A, B lines, pulmonary congestion-bat wings haziness, Cephalization of veins, pleural effusions
![Page 11: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/11.jpg)
• ECG- LA enlargement ,arrhythmias , LVH, previous MI• Echocardiography-assesment of systolic / diastolic
function, EF calculation ,any valvular abnormality ,abnormal wall motion
![Page 12: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/12.jpg)
• Biomarker of HF NP-useful in diagnosis,assessing severity
predicting short & long-term CVS mortality
• No HF- BNP <100pg/dl , PRO-BNP < 300pg/dl
• HF- BNP >500pg/dl , PRO-BNP >1000pg/dl
• 80% Sensitivity for heart failure
![Page 13: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/13.jpg)
Other tests
• CBC, SE, KFT, LFT, RBS, lipid profile, thyroid function test, CKMB, cardiac TnI/TnT,
• MRI-Gold standard for assesing cardiac mass or volume • Nuclear Studies-Exercise or pharmacologic stress nuclear
SPECT imaging with thallium 201 or Tc 99 may detect ischemia or previous MI and also assess LV function.
• Pulmonary artery catheter may be necessary in selected patients to obtain a more accurate and comprehensive hemodynamic profile during hospitalization
![Page 14: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/14.jpg)
Differential diagnosis
• MI• Tension PTX• Aortic dissection• PE• Asthma or COPD exacerbation• Cardiac tamponade• Ruptured viscus• Valvular abnormalities
![Page 15: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/15.jpg)
Goals of treatment in acute heart failure
![Page 16: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/16.jpg)
Management in the emergency dept.• Diagnosis and treatment are usually carried out in parallel,• Close monitoring of the patient’s vital functions is essential during the initial
evaluation and treatment
![Page 17: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/17.jpg)
Algorithm for management of acute pulmonary oedema/congestion
![Page 18: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/18.jpg)
![Page 19: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/19.jpg)
Pharmacological therapy in acute management
• Oxygen should be given to all hypoxaemic pts maintain SaO2 95–98%
• Patent airway should be ensured and FiO2 can be increased
• In non-hypoxaemic patients it causes vasoconstriction and a reduction in cardiac output.
![Page 20: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/20.jpg)
Diuretics use
• Indicated in symptoms secondary to fluid retention.• Most patients with dyspnoea in AHF caused by pulmonary
oedema • Rapid symptomatic relief by immediate venodilator action and
subsequent removal of fluid.• Start with individualized dose depending on clinical condition
![Page 21: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/21.jpg)
Diuretic dosing and administration
![Page 22: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/22.jpg)
Opiates(Morphine)
• Indicated in early stage of severe AHF associated with restlessness and dyspnoea.
• Morphine induces venodilatation and mild arterial dilatation, and reduces heart rate
• Morphine sulfate 2-5 mg iv over 2-3 mins and can be repeated every 10 to 25 mins until effect is seen
• Opiates induce nausea and depress respiratory drive potentially increasing the need for invasive ventilation
![Page 23: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/23.jpg)
Vasodilators• First line therapy in AHF with an adequate BP and signs of
congestion with low diuresis• Nitrates causes venous and arterial balanced
vasodilation,reduce LV pre-load and after-load, without impairing tissue perfusion.
• Sodium nitroprusside used in severe HF with predominantly increased after-load (hypertensive HF or MR)
• Nesiritide-Recombinant human BNP with venous, arterial, and coronary vasodilatory properties reduce preload and after-load, increase CO without direct inotropic effects.
• Calcium antagonists-Not recommended in treatment of AHF
![Page 24: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/24.jpg)
Indications and dosing of vasodilators in AHF
![Page 25: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/25.jpg)
Inotropes
• Reserved for pts with severely reduced cardiac output compromised vital organ perfusion
• Inotropes cause sinus tachycardia and may induce myocardial ischaemia and arrhythmias.
• There is long-standing concern that they may increase mortality
• Levosimendan, milrinone can counteract the effect of a beta-blocker
![Page 26: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/26.jpg)
Vasopressors
• In cardiogenic shock. • When the combination of inotropic agent and fluid challenge
fails to restore adequate arterial pressure and organ perfusion. • Peripheral arterial vasoconstrictor action raise blood pressure
and redistribute cardiac output from the extremities to the vital organs.
• It may increase the after-load of a failing heart and further decrease end-organ blood flow
![Page 27: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/27.jpg)
Drugs used to treat AHF thatare positive inotropes or vasopressors or both
![Page 28: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/28.jpg)
Use of inotropic drugs in AHF
![Page 29: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/29.jpg)
Other pharmacological therapy
• Cardiac glycosides – used in AF induced heart failure with insufficient ventricular rate-control by b-blockers.
• IV Beta Blocker should not be started during the initial phase of AHFS as acutely decrease cardiac contractility.
• However, a short-acting IV agent(esmolol) may be considered when AHF is ppt. by AF or flutter with a rapid ventricular response
• Anticoagulation-in ACS with or without HF, in AF and to prevent thrombo-embolism.
![Page 30: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/30.jpg)
Non-pharmacological therapy
• Restrict Na intake 2g/day and fluid intake 1.5–2.0 l/day• Non-invasive ventilation- CPAP/NIPPV used when increased
FiO2 fail to improve tissue oxygenation.• Endotracheal intubation and invasive ventilation- Reverse
AHF-induced respiratory muscle fatigue, acute respiratory failure not responding to vasodilators/oxygen therapy/CPAP/NIPPV.
• Mechanical circulatory support- IABP,VAD• Venovenous isolated ultrafiltration reserved for diuretics
resistant/unresponsive cases
![Page 31: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/31.jpg)
Mechanical assist devices
![Page 32: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/32.jpg)
After stabilisation• Diuretics often switched from an IV to an oral form. • Drugs Known to Improve Outcomes in HF- ACEI/ARB, beta
blockers, aldosterone blocking agents should be started as soon as possible
• The DIG trial showed that the addition of digoxin to ACE inhibitors and diuretics reduces rehospitalizations and, in retrospect, mortality in patients with serum concentration of the drug <1 ng/mL
![Page 33: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/33.jpg)
Underlying diseases and co-morbiditiesin AHF
• Underlying cause should be treated-CAD ,valvular disease, aortic dissection, hypertension,arrhythmias
• Precipitating factors -thyrotoxicosis crisis ,anaemia,• Co-morbidities -infections,diabetes, catabolic state,
renal failure ,pulmonary diseases etc. should be identified and treated
![Page 34: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/34.jpg)
Surgical treatment of AHF Treatment options - not often used in heart failure unless there is
a correctable problem• CABG• Angioplasty• Valve repair/replacement –AS,AR,MR.• Defibrillator implantation• Heart transplantation
![Page 35: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/35.jpg)
Pre-discharge and long-term management
• Before discharge pts should be free of dyspnea/symptomatic hypotension while at rest, washing, and walking on the ward.
• At least 24h of stable fluid status, BP and renal function • Stable oral diuretic regimen for at least 48 h.• Long-term disease-modifying therapy optimized as much as
possible • Appropriate education provided to the patient and
family/caregivers. • Follow-up - within approximately 1 month after discharge• Closer follow-up within 7-14 days and early telephone f/u
within 3 days.
![Page 36: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/36.jpg)
Potential newer therapies
• Soluble guanylate cyclase inhibitor – cinaciguat• Chimeric natriuretic peptide• Direct renin inhibitor - Aliskiren• Adenosine antagonist - Rolofylline• Ularitide• Endothelin antagonist - Tezosentan• Cardiac myosite activator – Omecamtiv mecarbil• Istaroxime• Stresscopin• Relaxin
![Page 37: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/37.jpg)
Prognosis
• Patients with AHF have a very poor prognosis. • AMI with severe HF, 12 month mortality 30%.• Acute pulmonary oedema-12% in-hospital and 40% 1
yr mortality have been reported.• About 45% of patients hospitalized with AHF will be
re-hospitalized at least once and 15% at least twice within 12 months.
• Risk of death/re-hospitalization within 60 days of admission vary from 30-60%, depending on the population studied
![Page 38: Management of acute lvf](https://reader036.vdocuments.net/reader036/viewer/2022062412/5877f0661a28ab20088b71f5/html5/thumbnails/38.jpg)
Thank you